Elan neurology news

Elan reached an agreement in principle with the U.S. Attorney's Office for the District of Massachusetts to settle an investigation by the U.S. Department of Justice into the company's sales and marketing practices for epilepsy drug Zonegran zonisamide. Elan will pay $203.5 million to settle claims by federal and state Medicaid agencies, plead guilty to a misdemeanor violation of the Food, Drug and Cosmetic Act and enter into a corporate integrity agreement with the office of the Inspector General of the U.S. Department of Health and Human Services. Elan, which launched Zonegran in 2000, divested U.S. rights to Zonegran to Eisai Co. Ltd. (Tokyo:4523; Osaka:4523, Tokyo, Japan) in 2004. ...